"Investors would have bought this at almost any price," added a Zurich banker.Besides its undisputed name recognition, a range of maturities to access different areas of demand and ratings of A1 (Moodys) and AA- (Fitch), Roche offered significant rarity value. The company last tapped its domestic market back ...
The rest of this content is available to subscribers and active trials only
Contact Jeremy Masters to discuss your access: email@example.com
To discuss GlobalCapital access for your entire department or company please call Jeremy Master on +44 (0)20 7779 8036 or email firstname.lastname@example.org to discuss your requirements.